{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-124081","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2024-11-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.083771+00:00","generated_at":"2026-05-29T12:53:08.636814+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Avenue Therapeutics receives Nasdaq delisting notice for equity deficiency; intends to request hearing","bullets":["Stockholders' equity of $1.652M as of Sep 30, 2024, below Nasdaq's $2.5M minimum requirement.","Delisting determined due to prior Panel Monitor; company ineligible for 180-day extension submission.","Trading continues; company must request hearing by Dec 3, 2024, to stay delisting.","Company believes equity compliance regained per Q3 10-Q Note 9; will demonstrate at hearing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-124081","json":"https://secwatch.observer/filing/0001104659-24-124081.json","markdown":"https://secwatch.observer/filing/0001104659-24-124081.md","text":"https://secwatch.observer/filing/0001104659-24-124081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000110465924124081/0001104659-24-124081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000110465924124081/tm2429840d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T12:53:08.636814+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3c039240c3c54e00cb0be293c312c6b9ba5d08c8","claim":"AVENUE THERAPEUTICS, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"least $2,500,000 (the “Stockholders’ Equity Requirement”). The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2024 reported stockholders’ equity of $1,652,000. In a decision dated June 3, 2024, a Nasdaq Hearings Panel (the “Panel”) previously had confirmed that the Company regained compliance with the Stockholders’ Equity","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465924124081/0001104659-24-124081-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}